Erasca Inc Stock Today
| ERAS Stock | USD 3.28 0.01 0.31% |
Performance14 of 100
| Odds Of DistressLess than 21
|
Erasca is selling for under 3.28 as of the 26th of July 2024; that is 0.31 percent increase since the beginning of the trading day. The stock's lowest day price was 3.2. Erasca has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Erasca Inc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of April 2024 and ending today, the 26th of July 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of July 2021 | Category Healthcare | Classification Health Care |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers. The company was incorporated in 2018 and is headquartered in San Diego, California. The company has 272.82 M outstanding shares of which 21.81 M shares are currently shorted by private and institutional investors with about 9.51 trading days to cover. More on Erasca Inc
Moving together with Erasca Stock
| 0.71 | PFE | Pfizer Inc Aggressive Push | PairCorr |
Moving against Erasca Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Erasca Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsErasca can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Erasca's financial leverage. It provides some insight into what part of Erasca's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Erasca Inc (ERAS) is traded on NASDAQ Exchange in USA. It is located in 3115 Merryfield Row, San Diego, CA, United States, 92121 and employs 126 people. Erasca is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 853.92 M. Erasca Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 272.82 M outstanding shares of which 21.81 M shares are currently shorted by private and institutional investors with about 9.51 trading days to cover.
Erasca Inc currently holds about 371.48 M in cash with (101.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04.
Check Erasca Probability Of Bankruptcy
Ownership AllocationErasca holds a total of 272.82 Million outstanding shares. Over half of Erasca's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Erasca Ownership Details
Erasca Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corporation | 2024-03-31 | 1.7 M | |
| Renaissance Technologies Corp | 2024-03-31 | 1.6 M | |
| Goldman Sachs Group Inc | 2024-03-31 | 1.6 M | |
| Cvi Holdings Llc | 2024-03-31 | 1.5 M | |
| Millennium Management Llc | 2024-03-31 | 1.2 M | |
| Point72 Asset Management, L.p. | 2024-03-31 | 1.1 M | |
| Two Sigma Investments Llc | 2024-03-31 | 1.1 M | |
| Two Sigma Advisers, Llc | 2024-03-31 | 1 M | |
| Woodline Partners Lp | 2024-03-31 | 890.8 K | |
| Arch Venture Corp | 2024-03-31 | 11.1 M | |
| Blackrock Inc | 2024-03-31 | 7 M |
Erasca Historical Income Statement
Erasca Stock Against Markets
Erasca Corporate Management
| Esq JD | General Secretary | Profile | |
| Michael Varney | Scientific Development | Profile | |
| Chandra Lovejoy | VP Affairs | Profile | |
| Lisa TesvichBonora | Chief Officer | Profile | |
| Nik Chetwyn | VP Operations | Profile | |
| CPA MS | VP Fin | Profile | |
| Wei MD | Chief Officer | Profile |
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.